Below is a complete list of the posters that will be presented at AAPP 2023. There will be two different poster sessions, and award finalists will present their posters on the same day as their platform presentation.

Click on the column headings to sort the table below, or click on a keyword next to a poster to filter by specific topic.

Use the search box to quickly locate an abstract by any data in the column, including "PGY2"! The site search provides full-text search of all 3,300+ abstracts that have been presented at the AAPP Annual Meeting over the years.

A Cross-Sectional Assessment of Perinatal Mental Health of Birthing People
A Pharmacodynamic Study Comparing IN Nalmefene to IN Naloxone in Healthy Volunteers
A Retrospective Review of Readmission Rates in Patients Initiated on Long-acting Injectable Antipsychotics During Psychiatric Hospitalization
A Search and Seizure for Relief- The Effective Pharmacological Treatment of Psychogenic Non-Epileptic Seizures (PNES) with Escitalopram
Absolute Neutrophil Count Monitoring in Clozapine Patients with a Point of Care Fingerstick Device: A Quality Improvement Research Project
Acting on the AUDIT-C: Implementation of Direct-to-Consumer Education on Unhealthy Alcohol Use
Addressing the Rising Stimulant Overdose Crisis With Academic Detailing
Agitation in the Emergency Department: Are patients that receive droperidol less likely to require rescue medications versus those that receive olanzapine
Analysis of Impact of COVID-19 Regulations on Mental Health Trends and Prescribing Patterns in an Institutionalized, Older Adult Population
Analysis of Psychiatric Pharmacist Telephone Outreach Interventions Using the Veterans Affairs National Academic Detailing Services Alcohol Use Disorder Dashboard 
Anticholinergic Ordering for Extrapyramidal Symptom (EPS) Prophylaxis and Incidence of EPS in Patients Treated With Antipsychotics
Antidepressant Medication Adherence in a Community Pharmacy Setting Before and After Onset of the COVID-19 Pandemic
Assessing As-Needed Medication Usage Frequency in Patients with Schizophrenia and Schizoaffective Disorder on Antipsychotic Medications for Acute Agitation
Assessing Behavioral Health Education and Training Needs of Pharmacy Personnel in Pennsylvania
Assessing the Appropriateness of Antipsychotic Prescribing Practices in Patients with Dementia in an Inpatient Community Living Center
Assessing the Efficacy of Battlefield Acupuncture for Reducing Pain Scores in Veterans Prescribed Opioid Therapy
Assessing the Impact of Culture and Stigma on the Utilization of Mental Health Resources Amongst Health Professions
Assessing Underutilization of Mental Health Resources at an HBCU
Assessment of an Integrated Psychiatric Pharmacy Practice within a Rural Internal Medicine Clinic
Assessment of Buprenorphine Prescribing Practices Overtime
Assessment of naloxone prescribing patterns before and after the introduction of South Carolina law requiring naloxone to be offered to patients at increased risk of opioid overdose
Association Between Suicide Attempt and Substance Use
Atypical Extrapyramidal Reaction to Haloperidol in a Young Hispanic Male
Augmentation With Antipsychotics In Child And Adolescent Patients With Major Depressive Disorder: A Retrospective Analysis Of Prescribing Patterns
Buprenorphine Initiation: Is opioid withdrawal necessary?
Buprenorphine Microdosing in Inpatients with Acute Infectious Illness: A Retrospective Cohort Study
Cardiovascular Safety of Amphetamine/ Dextroamphetamine Versus Methylphenidate in Older Adults
Centering Rural Veterans’ Experiences of SUD Care from Clinical Pharmacy Practitioners in VA: Patient Voices as an Implementation Metric
Changes in Metabolic Parameters Associated With Lumateperone in Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder
Characterization of Viloxazine’s Serotonergic Effects at Doses Relevant for ADHD Treatment
Clinical and Financial Outcomes of a Pharmacist Medication Management Program in an Outpatient Neurologic and Psychiatric Health Care Center
Clinical Conundrums of Clozapine on Consult Liaison Psychiatry
Clinical Implications of High-Dose Benzodiazepine Use in Veterans Prescribed Ketamine or Esketamine for Treatment-Resistant Depression or Suicidal Ideation.
Clinical Pharmacist Intervention to Ensure Safe Stimulant Prescribing Practices at a Veterans Affairs Facility
Clinical Pharmacy Impact in Mental Health Intensive Case Management
Clozapine and Respiratory Depression: A Case Report
Clozapine and Risk of Hematologic Malignancies in Veterans with Schizophrenia
Clozapine in Black Patients with Tardive Dyskinesia: Results of a 24 Week Open Label Clinical Trial
Comparing the Efficacy of Incorporating Intramuscular Midazolam or Lorazepam, or no Benzodiazepine, in Combination with Haloperidol and Diphenhydramine for the Treatment of Acute Agitation
Comparing the Pharmacokinetics, Efficacy, Tolerability, and Accessibility of Viloxazine versus Atomoxetine
Comparison of Long-acting Injectable Antipsychotics with Oral Antipsychotics and Hospital Readmission Rates at 3 Months in Pediatric Patients
Comparison of Propofol and Methohexital as Anesthetic Agents for Electroconvulsive Therapy
Comparison of Safety, Efficacy, and Appropriateness of Dalfampridine Therapy Pre and Post PharmD Intervention: A Retrospective Chart Review
Comparison of Weight-Based Valproic Acid Dosing in Treatment of Mental Illness Among Obese and Non-Obese Patients
Comprehensive Chart Evaluations by a Psychiatric Pharmacist in a Community Living Center to Improve Patient Safety Outcomes
Cost-Avoidance Analysis of Clinical Pharmacist Interventions on Antipsychotic Therapy in Acute Care Psychiatry in an Indigent Minority Population
Cost-Effective Analysis Between Valbenazine and Deutetrabenazine in a Veteran Population
Cross-Mapping the Outpatient Best Practice Model Statements with BCPP and CMM Components
Crushing Valbenazine Capsule Contents for Potential Addition to Soft Foods or Administration Via G Tube
Determining Actionable Veterans for Completion of Pharmacogenomic Testing to Guide Medication Therapy for Post-Traumatic Stress Disorder
Developing Ambulatory Care Clinical Pharmacy Services in a Gender Health Program
Developing Site-Specific Guidelines for Gender-Affirming Care at a Forensic Psychiatric Hospital
Development of the Core Outcome Set for Psychiatric Pharmacists
Don’t be Rash: Risk of cutaneous reactions from rapid retitration of lamotrigine
Effect of Direct-to-Consumer Education Plus Pharmacist Outreach on Benzodiazepine Prescribing in Veterans with Posttraumatic Stress Disorder
Effectiveness of Group Battlefield Acupuncture to Reduce Pharmacologic Pain Medication Utilization
Effectiveness of Mood Stabilizers Versus Second-Generation Antipsychotics for Pediatric Bipolar Disorder
Effects Of A Psychiatric PharmD Rotation On Mental Health Knowledge And Attitudes Towards The Provision Of Pharmaceutical Care To People With Mental Illness
Efficacy and Safety Comparison of Weekly/monthly Extended-release Injectable Buprenorphine (CAM2038) vs Daily Sublingual Buprenorphine/naloxone (BPN/NX) for Treatment of Patients with OUD Who Inject Opioids or Use Heroin.
Efficacy and Safety of Iloperidone in Acute and Mixed Mania Associated with Bipolar I Disorder: A Double-Blind, Placebo-Controlled, Phase III Study
Efficacy and Safety of Zuranolone in Adults With Major Depressive Disorder With and Without Use of Standard-of-Care Antidepressants at Baseline in the LANDSCAPE Clinical Development Program
Efficacy of Long-Acting Injectable Antipsychotics versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations
Esketamine Nasal Spray Versus Quetiapine Extended Release in Patients With Treatment-Resistant Depression: A Subgroup Analysis of the ESCAPE-TRD Study
Establishing a Collaborative Practice Agreement with Prescriptive Authority in a Local Mental Health Authority (LMHA)
Evaluating a Novel Pharmacist-Led Buprenorphine Outreach Service for Treatment of Opioid Use Disorder in Individuals Residing in Supportive Housing
Evaluating Outcomes of the Miami Veteran’s Affairs Healthcare System Syringe Service Program
Evaluating Provider Perception on the Role of Naloxone Use in Veterans with Stimulant Use Disorder (StimUD)
Evaluating the Impact of COVID-19 Hospitalization on New-Onset Depression, Dementia, and Healthcare Utilization in a Nationwide Veterans Health Administration Observational Cohort Study
Evaluating the Impact of Photovoice on Self-Stigma Levels Among Individuals with Substance Use Concerns
Evaluating the Impact of Psychiatric Pharmacists in a Developmental Disabilities Clinic
Evaluating the Usefulness of Culturally-Sensitive Mental Health Resources for PharmD Students and Graduate Students
Evaluation of Antipsychotic Monitoring in a Community Health Center during the COVID-19 Pandemic
Evaluation of Appropriate Lithium Monitoring in a Hospital System
Evaluation of Changes in Clozapine Prescribing Patterns Among Providers at VAPORHCS Following Expansion of Prescribing Privileges within VA Practice
Evaluation of Major Adverse Events and Drug Discontinuation of Clozapine Based on Accordance to an International Adult Titration Guideline
Evaluation of Medicaid Prescriber Report Card Intervention to Promote Appropriate Prescribing and Monitoring of Antipsychotics to Philadelphia’s Youths.
Evaluation of Medications for Opioid Use Disorder Utilization During Medical Inpatient Hospitalization
Evaluation of Rehospitalization Rates for Alcohol Use Disorder Management in the Inpatient Veteran Setting Based on Alcohol Use Disorder Medication Initiation
Evaluation of the Impact of a Mental Health Pharmacist in the Care of Veterans with Early Psychosis
Evaluation of Veterans on Buprenorphine-based Products for Opioid Use Disorder Who are Stable for Step-Down Treatment from Specialty Care
Examining Mental Health Effects of Hormonal Contraceptives in Women Veterans
Examining The Clinical Utility Of Pharmacist-Led Service Reviewing Aberrant Urine Drug Screens
Examining the Efficacy and Safety of Intravenous Ketamine vs. Intranasal Esketamine for Treatment Resistant Depression
Expanding Access to Pre-Exposure Prophylaxis (PrEP) to Veterans Who Inject Drugs
Exploring the Impact of a Psychiatric Pharmacist in Resolving Drug Therapy Problems and Improving Patient Outcomes at a Mental Health Center
Exploring the Influence of Psychosocial Interventions on Cancer Treatment Outcomes in Patients with Co-morbid Mental Health Conditions
Factors Affecting Treatment Retention for Long-Acting Injectable Antipsychotics
Gender Health Client Perceptions of Clinical Psychiatric Pharmacist Interactions: A Convergent Parallel Mixed Method Study
Historical Use of Phenobarbital for Alcohol Withdrawal Syndrome at an Academic Medical Center
Identifying Predictors of Adherence to Long-acting Naltrexone Injection Following Discharge from an Acute Inpatient Psychiatric Unit
Impact Of A Community Immersion Experience On Student Pharmacists' Associated Stigma Of Serious Mental Illness
Impact of a Pharmacist-driven Tardive Dyskinesia Education Service on Adherence to Recommended AIMS Monitoring
Impact of an Alcohol Use Disorder Order Set in the Emergency Department on Veteran Care and Health Outcomes
Impact of Antipsychotic-Induced Weight Gain on Discontinuation of Oral Second-Generation Antipsychotics at a Veterans Hospital
Impact of Depression Support Text Message Intervention
Impact of Early Peer Specialist Involvement on Medication Assisted Treatment Engagement and Treatment Retention in Patients with Substance Use Disorders
Impact of mental health clinical pharmacist practitioner services within a Veterans Affairs Clinical Resource Hub
Impact of Mental Health Clinical Pharmacy Practitioners Providing Measurement Based Care through Clinical Resource Hub
Impact of Participation in an Adolescent Medication Group on Pharmacy Intern Implementation and Knowledge of Psychotropic Medications and Patient Outcomes
Impact of Patient Support Programs on Clozapine Persistence and Cost: A Canadian Perspective
Impact of Therapeutic Drug Level Monitoring of Antipsychotics in Treatment Management at an Inpatient Psychiatric Hospital
Impact of Triptan and CGRP Receptor Antagonist Utilization on Plan Management for an Employer-Sponsored Health Plan for a Large Academic Medical Center
Implementation and Analysis of Harm Reduction Education Groups for Behavioral Health Patients  
Implementation and Evaluation of PHASER Pharmacogenetic Testing Program in a Veterans Affairs Mental Health Setting
Implementation and Outcomes of a Behavioral Health Integration Program: A Focus on Post-discharge Follow-up and Transitions of Care
Implementation of a Harm Reduction Program at the West Palm Beach VA Health Care System
Implementation of a MAT Program in a County Jail
Implementation of a Multiple Antipsychotic Pharmacy Consult at a Veterans Affairs Health Care System
Implementation of a Pharmacist-Driven Antipsychotic Taper Protocol for Acute Agitation and/or Delirious Hospitalized Patients
Implementation of a pharmacist-led suicide and overdose risk mitigation clinic at a VA Medical Center
Implementation of a Virtual Interprofessional Geriatric Mental Health Service
Implementation of an Ambulatory Alcohol Detoxification Clinic at a Veterans Affairs Medical Center
Implementation of harm reduction services at a Veteran's Affairs (VA) facility
Implementation of Psychiatric Pharmacists at Academic Medical Center
Implementing Naloxone Kit Distribution in a Veterans Affairs Hospital Emergency Department
Implementing Standardized Ketamine Dosing for Treatment Resistant Depression
Implications of Clozapine Monitoring During the COVID-19 Pandemic
Improvements in Cognitive and Physical Functioning Outcomes in Depressed Patients Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-Label, Long-Term Study
Improving Hemoglobin A1c Monitoring of Veterans on Second-Generation Antipsychotics through Implementation of an Expanded Ordering Template
Improving Management of Opioid Withdrawal Symptoms on an Inpatient Psychiatry Unit at Salem Veterans Affairs Health Care System
Incidence of Anti-hypertensive Therapy Initiation in Patients Taking Serotonin and Norepinephrine Reuptake Inhibitors: An Evaluation of Prescribing Cascades at Gundersen Health System
Increasing Naloxone Prescription Rates in a Veteran Population with Stimulant Use Disorder Through Combination Pharmacist Outreach and Education to Mental Health Professionals
Increasing the Dispensing of Naloxone to At-Risk Patients in the Emergency Department
Inflammation with Intolerance after Early Clozapine Exposure: A Rationale for Early CRP Monitoring Beyond Myocarditis
Interim Analysis of Efficacy During Long-Term Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Open-Label Extension Study
Investigation of Changes in Naltrexone Long-Acting Injection Use Due to COVID-19 Pandemic
Is a Partial Initiation of Paliperidone Palmitate Effective at Reducing Emergency Psychiatric Encounters?
Is Early Response the More Appropriate Outcome for Depression Studies?
Knowledge of Pharmacists' Role in the Management of Opioid Use Disorder: Pharmacy Students' Perspective
Lithium Dosing in Post-Transplant Patient with Unstable Fluid-Electrolyte Status: A Case Report
Long-Term Efficacy of Treatment with Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder: Results from an Open-Label Extension Study
Long-Term Lumateperone Treatment in Bipolar Disorder: Six-Month Open-label Extension Study
Long-term Retrospective Study of Weight Change in Cannabis Positive Outpatients with Schizophrenia or Bipolar 1 Disorder receiving treatment with Olanzapine/samidorphan vs Olanzapine Alone.
Long-Term Safety and Symptom Trajectory With Aripiprazole Lauroxil in Female Patients With Schizophrenia: A Post Hoc Subgroup Analysis
Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: Evaluation of Extrapyramidal and Motor Symptoms in Late-Phase Clinical Trials
Medical Cannabis in the Treatment of Parkinson’s Disease
Medication Utilization for Managing Agitated Patients Based on Implicit Bias
Methodology for Evaluating the REMS Programs for Psychiatric Medications
Myoclonic Jerks Following Clozapine Initiation
Naloxone Co-Prescribing Practices for High-Risk Patients in an Academic Medical Center Family Medicine Clinic
Naloxone Prescribing and Clinical Pharmacy Specialist Interventions at the Cincinnati Veterans Affairs Medical Center (CVAMC)
Neuroleptic Malignancy Syndrome? Benzodiazepine Withdrawal? Both?: A Case Report
Newer Antiseizure Medications and Suicidality: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Nudging Behavioral Changes: Evidence from Healthy Eating Challenge
Optimizing Antipsychotic Dosing Through a Pharmacy Driven Evidence-Based Titration Schedule: a Retrospective, Prospective, Quality-Improvement Study
Optimizing Collaboration Among Clinical Pharmacy Specialists and Behavioral Health Providers in The Primary Care Setting
Outreach Visits by Pharmacist Improves Adherence to Long-Acting Injectable Antipsychotics in a Rural Setting
Paliperidone Palmitate And Prazosin-Induced Retrograde Ejaculation In A Psychiatrically Stabilized Patient With Bipolar I Disorder
Patient Characteristics Associated with Episodes of Agitation
Patient-Experienced Stigma: Perceptions Regarding Obtaining Prescription Stimulant ADHD Medications
Pharmacist Impact on Administration Intervals and Appropriate Titration of Long-Acting Injectable Antipsychotics (LAIAs) through Monitoring, Alerts, and Interventions
Pharmacist Impact on Expanding Naloxone Access and Distribution to Patients with Stimulant Use Disorders via Targeted Secure Messaging
Pharmacist Reported Protocols for QTc Monitoring for Psychiatric Medications
Pharmacist-Based Medication Reconciliation for High-Risk Community Patients
Pharmacist-Conducted Comprehensive Psychiatric Medication Reviews of Hospitalized Psychiatric Inpatients
Pharmacist-Led Optimization of Discharge Medication Reconciliation for Long-Acting Injectable Antipsychotics
Pharmacists Teaming Up in the University Outpatient Psychiatric Clinic to Effectively Implement Pharmacogenomics Clinical Services
Pharmacogenomic Testing in Veterans with Treatment Resistant Major Depressive Disorder (MDD)
Pharmacogenomics (PGx) in the Electronic Health Record (EHR)
Pharmacotherapy for Pediatric and Adolescent Agitation in an Inpatient Behavioral Health Unit
Picking the Brain: Treatment of Amphetamine/Dextroamphetamine Induced Excoriation Disorder
Piloting an Outpatient Pharmacy Mental Health Consultation Service
Policies and Recommendation Frequencies for Medications for Opioid Use Disorder in Professional Recovery Programs in the U.S.
Postictal Agitation After Electroconvulsive Therapy: Risk Factors and Treatment
Potential Benefit of Naltrexone in a Patient with Autistic Disorder and Borderline Personality Disorder Exhibiting Self Injurious Behaviors
Preliminary Evaluation of Psychiatric Pharmacist Services in the Outpatient Setting
Prevalence of and Factors Associated with Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs) Concurrent Prescribing Among Texas Medicaid Adults
Prevalence of Drugs of Abuse Usage in Veterans with ADHD treated with Stimulants vs. Non-Stimulants
Protocol for a Multi-Site Study Implementing a Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder in Primary Care
Psychotropic Stewardship: Advancing Patient Care
Quality Improvement for Metabolic Monitoring of Children and Adolescents Prescribed an Antipsychotic
Rapid Antidepressant Effects of Zuranolone in Patients With Major Depressive Disorder and Postpartum Depression: Overview of the LANDSCAPE and NEST Clinical Development Programs
Real World Impact of Patients with Bipolar Disorder or Schizophrenia who Experience High Frequency of Agitation Episodes
Real-World Adherence to Deutetrabenazine or Valbenazine Among Patients With Tardive Dyskinesia
Real-World Effectiveness and Safety of Deutetrabenazine in Combination with Antipsychotic Drugs in Patients With Chorea Associated With Huntington Disease
Real-World Insights Into Long-Acting Injectable Antipsychotic Agent (LAI) Initiation in the Inpatient Setting and Transition/Continuation-of-Care: Impact of LAI Characteristics on Outcomes Among Patients With Schizophrenia
Retrospective Review of Racial Disparities in Treatment of Agitation in an Academic Medical Center
Review of the TAAR1 Agonist Ulotaront: Part I - from Discovery to Clinic
Review of the TAAR1 Agonist Ulotaront: Part II - Summary of Initial Clinical Efficacy/Safety Results
Safety and Effectiveness Outcomes of Conversion of Intravenous Ketamine or Intranasal Esketamine to Intramuscular Ketamine
Safety and Efficacy of KarXT (Xanomeline–Trospium) in Schizophrenia in the Phase 3, Randomized, Double-Blind, Placebo-Controlled EMERGENT-2 Trial
Safety of Deutetrabenazine Above Food and Drug Administration Maximum Recommended Dose in Huntington’s Disease Chorea
Self-Stigma of Depression Among Pharmacy Students
Standardization of Long-acting Injectable Antipsychotic Documentation at a Veterans Affairs Healthcare System
Subcutaneous Risperidone (TV-46000) Efficacy in Schizophrenia: A Phase 3, Randomized, Double-Blind, Relapse Prevention Study (RISE Study)
Subcutaneous Risperidone (TV-46000) Safety and Tolerability in Schizophrenia: A Phase 3, Randomized, Double-Blind, Relapse Prevention Study (RISE Study)
Sublingual Dexmedetomidine for the Treatment of Acute Agitation Associated with Schizophrenia or Bipolar Disorder: Effect Size and Pooled Efficacy
Successful Transition of Patients Referred to a Hospital-Affiliated Long-Acting Therapy Clinic After Inpatient Hospital Stay: A Transitions of Care Analysis
Sustained Treatment Response with Long-Term Valbenazine in Patients with Tardive Dyskinesia
Systematic Literature Review of the Impact of Psychiatric Pharmacists
The Development and Implementation of an Intensive Substance Use Disorders Curriculum in a Professional Pharmacy Program
The Development and Implementation of Best Practices to Reduce Burnout, Promote Healing, and Revive Inspiration in Psychiatric Clinical Pharmacist Practitioners at a Veteran’s Hospital
The Effect of Appropriate Utilization of Medications for Opioid Use Disorder (MOUD) on Length of Stay and Readmission in Patients at the Middle Tennessee Mental Health Institute (MTMHI)
The Impact of Antiseizure Medication on Cardiac Function
The Impact of Multiple Antipsychotics in Treatment-Resistant Psychosis at a Forensic Psychiatric Hospital
The Implementation of Controlled Central Nervous System Stimulant Medical Monitoring Outreach at a Veterans Affairs Hospital
The Myoclonus Mystery: A Case of Lance-Adams Syndrome Complicated by Withdrawal Seizures of Alcohol Use Disorder
The Relationship Between Opioid Overdose Death Rates and Buprenorphine Distribution to Retail Pharmacies in California in 2021
There’s no place like home: Clinical Pharmacist Practitioners collaborate with X-waivered providers to provide buprenorphine via home initiations during the COVID-19 pandemic
Time-to-Therapy Discontinuation in Patients Newly Diagnosed with Schizophrenia Initiated on Long-Acting Injectable Versus Oral Dopamine Receptor Blocking Agents
Title: Buprenorphine Enhanced Taper Tolerability Evaluation Report: A Case Report
Title: Efficacy of Liraglutide in Comparison to Metformin for the Management of Antipsychotic-Induced Weight Gain
Training Pharmacy Students to Administer Long-Acting Injectable Medications
Trazodone versus Doxepin as a Pharmacologic Sleep Aid in Psychiatric Inpatients: A Retrospective Cohort Study
Treatment Outcomes of Topiramate in Comorbid Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD) in Veterans
Tricyclic Antidepressant Serum Concentration Monitoring at an Inpatient Psychiatric Hospital
Understanding Adverse Drug Reactions: The Impact of Prescriber and Nurse Education at a State Psychiatric Hospital
Use of Asenapine in a Patient Concerned About Weight Gain with Olanzapine
Use of Emergent Intramuscular Diphenhydramine, Haloperidol, and Midazolam in Acute Agitation Management in Patients with Psychiatric Conditions
Use of Prazosin, an Alpha-1 Adrenergic Blocker, in Children with PTSD-Associated Nightmares
Use of Short-Acting Injectable Antipsychotics for Management of Acute Agitation in Adult Inpatient Psychiatry
Utility of DEA-Licensed Pharmacist as Primary Prescriber in Benzodiazepine Taper Clinic
Utilization and Appropriateness of Single Dose Injectable Aripiprazole Lauroxil in the Treatment of Schizophrenia
Utilization of a State-wide Health Information Exchange for Contingency Management in a Behavioral Health Population
Utilization of Extended-Release Buprenorphine Injection to Transition Off of Oral Buprenorphine/Naloxone for Opioid Use Disorder: A Case Series
Utilization of Medication for Opioid Use Disorder in Opioid Treatment Programs
Validation Of An Algorithm For The Assessment, Management and Monitoring of Drug-induced QTc Prolongation In The Psychiatric Population
Words Matter: Analysis of the Language Used When Documenting in the Medical Records of Mental Health Patients